Therapeutic Effects of HESA-A in Patients With End-Stage Metastatic Cancers

Abstract

Background: After cardiovascular disease, cancer is the most common cause of death. HESA-A is a natural product of herbal and marine origin. The aim of this study was to investigate the beneficial effects of HESA-A in patients with end-stage metastatic cancers. Methods: In this clinical trial, 30 consecutive patients (18 men, 12 women) with end-stage cancers and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied. Patients received HESA-A 50 mg/kg/d orally in 2 to 3 divided doses for 3 months. At the start and end of the 1st, 4th, 8th, and 12th weeks of the study, the patients were assessed and hematological and hepatic biochemical indices were measured. Also, the Karnofsky Performance Scale questionnaire was completed for each patient. Results: The mean age of patients was 56.23 ± 12.10 years. Mean Karnofsky Performance Scale scores of the patients increased from 48 ± 14.36 to 78.42 ± 15.37 after 12 weeks of treatment. A total of 90.4% of the patients who remained in the study were alive for 12 weeks. No significant hepatic or hematologic adverse effect was seen during the study. Conclusion: HESA-A appears to be an effective and safe anticancer compound that may increase survival of end-stage patients and can be used in selected cases. Further prospective controlled clinical trials with large sample size and longer follow-up period are warranted to understand the mechanisms of action of HESA-A and evaluate its long-term effects on the survival and quality of life of patients with cancer and as well as its unfavorable side effects.

Keywords

HESA-A cancer antioxidant side effects

References

Mackenbach JP , Huisman M. , Andersen O. , et al. Inequalities in lung cancer mortality by the educational level in 10 European populations. Eur J Cancer. 2004;40:126-135.

Collier DA , Neidle S. Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthroquinones. J Med Chem. 1988;31:847-857.

Costello AJ A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology . 2001;57:182-184.

Burk RF Selenium, and antioxidant nutrient. Nutr Clin Care. 2002;5:75-77.

Wang GQ , Dawsey SM , Li JY , et al. Effects of vitamin/ mineral supplementation on the prevalence of histological dysplasia and early cancer of esophagus and stomach: results from the general population trial in Linxian, China. Cancer Epidemol Biomarkers Prev. 1994;3:161-166.

Melendez E. Titanium complex in cancer treatment. Crit Rev Oncol Hematol . 2002;142:309-315.

Fernandez-Banares F. , Cabre E. , Esteve M. , et al. Serum selenium and risk of large colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol. 2002; 97:2103-2108.

Denkhaus SE , Salinkow K. Nickel essentiality, toxicity and carcinogenicity. Crit Rev Oncol Hematol. 2002;42:35-56.

Ji YJ , Xiao B. , Wang ZH , Cui MZ , Lu YY The suppression effect of light rare earth elements on proliferation of two cancer cell lines. Biomed Environ Sci. 2000 ;13:287-292.

10.

Evangelov AM Vanadium in cancer treatment. Crit Rev Oncol Hematol. 2002;42:249-256.

11.

Hiraoka K. , Komiya S. , Hamada T. , Zenmyo M. , Inove A. Osteosarcoma cell apoptosis induced by selenium. J Orthp Res . 2001;19:809-814.

12.

Ahmadi A. , inventor. Method of preparation of an antitumor herbal drug [HESA-A]. Islamic Republic of Iran patent 27741. 2002.

13.

Ahmadi A. , Naderi G. , Asgary S. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005;31:1-6.

14.

Ahmadi A. , Sadeghi Aliabadi H. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru. 2003;11:82-87.

15.

Zeng H. , Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008;19:1-7.

16.

Caruso F. , Rossi M. Antitumor titanium compounds. Mini Rev Med Chem. 2004;4:49-60.

17.

Guo J. , Deng W. , Zhang L. , Li C. , Wu P. , Mao P. Prediction of prostate cancer using hair trace element concentration and support vector machine method. Biol Trace Elem Res. 2007; 116:257-272.

18.

Hajhashemi V. , Ghafghazi T. , Balali M. , et al. Toxicological studies on an anticancer drug (HESA-A) with marine origin. Med J Islam Acad Sci. 2001;14:145-149.

19.

Ahmadi A. , Mohgheghi MA , Sharif-Tabrizi A. Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. In: Proceedings of the First National Congress on Cancer Research, Orumiah, Iran; 2001:5-8.

20.

Sadeghi-Aliabadi H. , Ahmadi A. Cytotoxicity and antitumor properties of a marine compound on cancer cell (HESA-A). Med J Islam Acad Sci. 2000;13:55-61.

21.

Fazly Bazzaz BS HESA-A, its cytotoxicity and mutagenicity . J Oncol Pharm Pract. 2006;12:60.

22.

Ahmadi A. Analysis of HESA: report of Atomic Energy Organization of Iran (AEOI), Research Division, Tehran, Islamic Republic of Iran, 2004.

23.

Ahmadi A. , Mohagheghi MA , Fazeli MS , et al. HESA-A: new treatment for breast cancer and choroidal metastasis . Med Sci Monit. 2005;11:CR300-CR303.

24.

Ahmadi A. , Mohagheghi M. , Karimi M. , Golestanha SA , Naseri M. Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr Cancer Ther. 2009;8: 71-74.